|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PNPLA3 148M is over-represented in ALD&NAFLD HCC patients, and is associated with occurrence at a less advanced stage of liver disease in ALD&NAFLD.
|
24155878 |
2013 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, the -1195GG genotype in COX-2 is a genetic marker for liver disease progression, while the PNPLA3 genotypes are not associated with disease progression in Japanese patients with chronic hepatitis C.
|
22863264 |
2012 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review describes the impact of genetic variants of interleukin 28B (IL28B; also known as interferon-lambda 3), inosine triphosphate pyrophosphatase (ITPA) and patatin-like phospholipase domain-containing 3 (PNPLA3) on therapeutic outcome and liver disease severity in HCV-infected patients.
|
26250055 |
2015 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic variation in both patatin-like phospholipase domain-containing protein-3 (PNPLA3) (I148M) and the transmembrane 6 superfamily member 2 protein (TM6SF2) (E167K) influences severity of liver disease, and serum triglyceride concentrations in non-alcoholic fatty liver disease (NAFLD), but whether either genotype influences the responses to treatments is uncertain.
|
26272871 |
2015 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recently, the rs738409 rs738409" genes_norm="80339">I148M patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism has been demonstrated to influence steatosis susceptibility and fibrosis progression in patients with different liver diseases, but no data are yet available for CHB.
|
23564580 |
2013 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Of note, the PNPLA3 risk variant advances fibrosis in the total cohort as well as in the subgroups of patients with viral hepatitis and non-viral liver diseases and contributes 16% of the total cirrhosis risk.
|
21168459 |
2011 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic variants of patatin-like phospholipase domain-containing 3 (PNPLA3) and diabetes are associated with liver disease severity, in patients with chronic hepatitis C (CHC) infection.
|
25457210 |
2015 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The rs738409 genetic variant in the patatin-like phospholipase domain-containing 3 (PNPLA3, adiponutrin) gene has been implicated as a genetic determinant of the entire spectrum of liver diseases, ranging from steatosis, chronic hepatitis, cirrhosis and ultimately to HCC.
|
23333103 |
2013 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent advances include the identification of PNPLA3 as a modifier of disease outcome across the full spectrum of NAFLD from steatosis to advanced fibrosis and hepatocellular carcinoma; and the discovery of TM6SF2 as a potential "master regulator" of metabolic syndrome outcome, determining not only risk of advanced liver disease, but also cardiovascular disease outcomes.
|
26378644 |
2015 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This review will explore the bidirectional relationship between metabolic syndrome and NAFLD, and will also discuss recent insights from studies of PNPLA3 and TM6SF2 genotypes that may give insight into how and why metabolic syndrome features and liver disease are linked in NAFLD.
|
26978356 |
2016 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study was conducted to determine whether PNPLA3 rs738409 SNPs affect development and prognosis of hepatocellular carcinoma (HCC) in patients with various liver diseases.
|
22869157 |
2013 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The objectives of this study were to determine the association between PNPLA3 and liver fibrosis severity, HCC risk, and HCC prognosis among patients with liver disease.
|
24445574 |
2014 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The G-allele in position rs738409 of patatin-like phospholipase domain-containing protein 3 (PNPLA3) is associated with an increased hepatic concentration of triglyceride and is a risk factor for advanced liver disease.
|
23872669 |
2013 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Defining the precise role of PNPLA3 in the liver lipid metabolism, in order to develop novel therapies for the treatment of liver disease, will be the key of future research.
|
29935383 |
2019 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A second ABC transporter, the hepatic phosphatidylcholine translocase ABCB4, increases the risk for gallstone disease, gallbladder cancer and chronic liver diseases in general, whereas the common PNPLA3 risk variant p.I148M decreases gallstone risk.
|
30608254 |
2019 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC.
|
30161167 |
2018 |
|
Liver diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In a few cases (e.g., patatin-like phospholipase domain-containing 3/adiponutrin), steatosis carries a high risk of both liver disease and cardiovascular morbidity/mortality; in other cases (e.g., transmembrane 6 superfamily 2 human gene), dissociation has been observed between the increased risk of liver disease versus cardiovascular disease.
|
27548720 |
2017 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The prevalence of possession of both PNPLA3 and GCKR variant alleles combined was significantly higher in at-risk patients with clinically significant liver disease indicated by serum PIIINP above 11 ng/mL (P = .014).
|
29493856 |
2018 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The presence of the TM6SF2 c.499A allele in the donor (p=0.014), the PNPLA3 c.444G allele in the donor (p<0.001), posttransplant BMI (p<0.001) and serum triglycerides (p=0.047) independently predicted increased liver fat content on multivariable analysis whereas noncirrhotic liver disease as an indication for liver transplantation was associated with lower risk of steatosis (p=0.003).
|
31356578 |
2020 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
|
30289982 |
2019 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Association of PNPLA3 Polymorphism with Hepatocellular Carcinoma Development and Prognosis in Viral and Non-Viral Chronic Liver Diseases.
|
26745088 |
2015 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We aimed to assess the prevalence of patatin-like phospholipase domain-containing 3 protein (PNPLA3) gene rs738409 C > G polymorphism in Brazilian individuals with type 2 diabetes and to investigate its association with liver disease severity, diabetic chronic degenerative complications, and metabolic control.
|
31377187 |
2019 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The patatin-like phospholipase domain-containing 3 gene (PNPLA3) and the apolipoprotein C3 gene (APOC3) have been studied in relation to liver steatosis and liver disease outcome.
|
23808989 |
2013 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These data indicate that PNPLA3 is required for HSC activation and that its genetic variant I148M potentiates the profibrogenic features of HSCs, providing a molecular mechanism for the higher risk of progression and severity of liver diseases conferred to patients carrying the I148M variant.(Hepatology 2017;65:1875-1890).
|
28073161 |
2017 |
|
Liver diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The presence of a PNPLA3 risk allele had no independent impact on liver disease or virological response rates to PEGIFN/RBV therapy in our cohort of HIV/HCV coinfected patients.
|
26599080 |
2015 |